Analysts Set Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Target Price at $24.17

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) has been given an average rating of “Hold” by the ten ratings firms that are covering the stock, Marketbeat reports. Seven analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $24.17.

A number of analysts recently issued reports on the company. Barclays upgraded Deciphera Pharmaceuticals from an “underweight” rating to an “equal weight” rating and boosted their price target for the company from $9.00 to $26.00 in a report on Tuesday, April 30th. JMP Securities reiterated a “market perform” rating on shares of Deciphera Pharmaceuticals in a report on Tuesday, April 30th. Jefferies Financial Group restated a “hold” rating and set a $25.60 target price (down previously from $26.00) on shares of Deciphera Pharmaceuticals in a report on Monday, April 29th. Guggenheim restated a “neutral” rating on shares of Deciphera Pharmaceuticals in a report on Tuesday, April 30th. Finally, Leerink Partnrs lowered Deciphera Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Monday, April 29th.

Deciphera Pharmaceuticals Price Performance

Shares of NASDAQ:DCPH opened at $25.59 on Tuesday. Deciphera Pharmaceuticals has a 1 year low of $9.90 and a 1 year high of $25.61. The business has a 50 day simple moving average of $23.53 and a two-hundred day simple moving average of $18.30. The firm has a market capitalization of $2.21 billion, a PE ratio of -11.58 and a beta of 0.19.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its earnings results on Friday, May 10th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.03. Deciphera Pharmaceuticals had a negative return on equity of 52.42% and a negative net margin of 108.86%. The business had revenue of $45.00 million during the quarter, compared to analyst estimates of $45.99 million. Equities research analysts expect that Deciphera Pharmaceuticals will post -2.15 EPS for the current fiscal year.

Hedge Funds Weigh In On Deciphera Pharmaceuticals

A number of large investors have recently made changes to their positions in the business. Jacobs Levy Equity Management Inc. increased its position in shares of Deciphera Pharmaceuticals by 11.3% during the first quarter. Jacobs Levy Equity Management Inc. now owns 471,977 shares of the company’s stock worth $7,424,000 after purchasing an additional 47,936 shares in the last quarter. Redmile Group LLC increased its position in shares of Deciphera Pharmaceuticals by 10.3% during the first quarter. Redmile Group LLC now owns 5,296,643 shares of the company’s stock worth $83,316,000 after purchasing an additional 495,103 shares in the last quarter. Public Employees Retirement System of Ohio acquired a new position in shares of Deciphera Pharmaceuticals during the first quarter worth $190,000. Price T Rowe Associates Inc. MD increased its position in shares of Deciphera Pharmaceuticals by 14.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 15,355 shares of the company’s stock worth $242,000 after purchasing an additional 1,984 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Deciphera Pharmaceuticals by 3.7% during the first quarter. Vanguard Group Inc. now owns 4,565,044 shares of the company’s stock worth $71,808,000 after purchasing an additional 163,408 shares in the last quarter. 70.96% of the stock is owned by institutional investors and hedge funds.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.